GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (NAS:SHPG) » Definitions » Capital Expenditure

Shire (SHPG) Capital Expenditure : $-797.90 Mil (TTM As of Sep. 2018)


View and export this data going back to 1998. Start your Free Trial

What is Shire Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Shire's cash flow for capital expenditures for the three months ended in Sep. 2018 was $-203 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Sep. 2018 was $-797.90 Mil.

Shire Capital Expenditure Historical Data

The historical data trend for Shire's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shire Capital Expenditure Chart

Shire Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -157.00 -77.00 -124.20 -648.70 -798.80

Shire Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -174.40 -233.30 -177.80 -183.50 -203.30

Shire Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-797.90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shire (SHPG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (NAS:SHPG) » Definitions » Capital Expenditure
Comparable Companies
VRTX REGN ASX:CSL ALXN XKRX:207940 SGEN INCY XKRX:068270 HKSE:01177 XBRU:UCB OCSE:GMAB HKSE:02269 BMRN HKSE:06160 XAMS:GLPG ALNY ARRY NBIX SZSE:300122 IONS
Traded in Other Exchanges
N/A
Address
Website
http://www.shire.com
Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.
Executives
James H Cavanaugh director 265 HOTHORPE LANE, VILLANOVA PA 19085